Kardigan, Inc. Research and Development Expense
Kardigan, Inc. (KARD) reported Research and Development Expense of $56.37 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-11
- Kardigan, Inc. research and development expense for the quarter ending 2026-06-30 was $56.37M, a 57.27% increase year-over-year.
- Kardigan, Inc. research and development expense for the quarter ending 2025-06-30 was $35.84M.
| Period end | Research and Development Expense 3 month | Research and Development Expense 6 month |
|---|---|---|
| 2026-06-30 | $56.37M 10-Q · filed 2026-08-11 | $101.43M 10-Q · filed 2026-08-11 |
| 2025-06-30 | $35.84M 10-Q · filed 2026-08-11 | $54.61M 10-Q · filed 2026-08-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| HARROW, INC. (HROW) | United States | $1.240B | -42.77 |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| OPKO HEALTH, INC. (OPK) | United States | $1.220B | -15.59 |